The economic impact of severe asthma to low-income families

Allergy. 2009 Mar;64(3):478-83. doi: 10.1111/j.1398-9995.2009.01981.x. Epub 2009 Feb 6.

Abstract

Background: To estimate the direct and indirect costs of severe asthma and the economic impact of its management to low-income families in Salvador, Brazil.

Methods: One hundred and ninety-seven patients with severe asthma and referred to a state-funded asthma center providing free treatment were evaluated. At registration, they were asked about family cost-events in the previous year and had a baseline assessment of lung function, symptoms and quality of life. During the subsequent year, they were reassessed prospectively.

Results: One hundred-eighty patients concluded a 12-month follow-up. Eighty-four percent were female patients, and the median family income was US$ 2955/year. Forty-seven percent of family members had lost their jobs because of asthma. Total cost of asthma management took 29% of family income. After proper treatment, asthma control scores improved by 50% and quality of life by 74%. The income of the families increased by US$ 711/year, as their members went back to work. The total cost of asthma to the families was reduced by a median US$ 789/family/year. Consequently, an annual surplus of US$ 1500/family became available.

Conclusions: Family costs of severe asthma consumed over one-fourth of the family income of the underprivileged population in a middle-income country. Adequate management brings major economic benefit to individuals and families.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Asthmatic Agents / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use
  • Asthma / drug therapy*
  • Asthma / economics*
  • Brazil
  • Bronchodilator Agents / therapeutic use
  • Budesonide / therapeutic use
  • Cost of Illness*
  • Ethanolamines / therapeutic use
  • Family
  • Female
  • Fenoterol / therapeutic use
  • Formoterol Fumarate
  • Humans
  • Male
  • Middle Aged
  • Poverty / economics*
  • Quality of Life
  • Rhinitis / drug therapy

Substances

  • Anti-Asthmatic Agents
  • Anti-Inflammatory Agents
  • Bronchodilator Agents
  • Ethanolamines
  • Fenoterol
  • Budesonide
  • Formoterol Fumarate